--- title: "BeyondSpring gets Nasdaq minimum bid price notice" url: "https://aibio.space/news/beyondspring-gets-nasdaq-minimum-bid-price-notice-has-until-march-16/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-09-18" section: "Listings" tickers: "NASDAQ:BYSI" source: "https://www.sec.gov/Archives/edgar/data/1677940/000117184326006116/f8k_091826.htm" summary: "Nasdaq told BeyondSpring on September 17, 2026 that its ordinary shares closed below $1.00 for 30 consecutive business days. Trading continues during a 180" --- By the aibio.space news desk. Sources - [BeyondSpring Inc. Form 8-K filed September 18, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1677940/000117184326006116/f8k_091826.htm) - [BeyondSpring Inc. Form 10-K filed March 25, 2026: business overview and signatures (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1677940/000117184326001908/bysi20251231_10k.htm) [BYSI](https://aibio.space/companies/beyondspring/) 2026-09-18 # BeyondSpring gets Nasdaq minimum bid price notice, has until March 16, 2027 Tickers [BYSI](https://aibio.space/companies/beyondspring/) Nasdaq told BeyondSpring on September 17, 2026 that its ordinary shares closed below $1.00 for 30 consecutive business days. Trading continues during a 180 calendar day compliance period that ends March 16, 2027. ## Key facts - **Company**: BeyondSpring, Inc. (NASDAQ: BYSI) - **News type**: Listings - **Primary source**: [BeyondSpring Inc. Form 8-K filed September 18, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1677940/000117184326006116/f8k_091826.htm) *The Capitol dome seen from below. Photo: U.S. Department of Homeland Security (Source), CC0, via rawpixel. The picture shows the field, not the companies named.* BeyondSpring Inc. received a Nasdaq minimum bid price deficiency notice on September 17, 2026, the company said in a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1677940/000117184326006116/f8k_091826.htm) filed September 18, 2026. The letter came from the Listing Qualifications Department of The Nasdaq Stock Market LLC. It says the closing bid price of the company's ordinary shares, par value $0.0001 per share, was below $1.00 for 30 consecutive business days. BeyondSpring therefore no longer complies with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). ## The compliance period The letter is a warning, not a delisting. The filing says it has no current immediate effect on the listing or trading of the ordinary shares, which will keep trading on Nasdaq during the period. Under Nasdaq Listing Rule 5810(c)(3)(A), BeyondSpring has 180 calendar days, or until March 16, 2027, to regain compliance. It regains compliance if the closing bid price is at or above $1.00 for at least ten consecutive business days before that date. If it has not done so by March 16, 2027, it may be eligible for an additional 180-day period, subject to the determination of the Nasdaq staff. ## What the company says BeyondSpring says the notice does not affect its business operations. It says it is considering all available options to regain compliance within the grace period. The filing adds that there can be no assurance it will regain compliance with the bid price requirement or stay in compliance with the other Nasdaq listing criteria. The 8-K does not describe any reverse stock split or other step the company has chosen. ## Cash and the auditor's history The annual report filed March 25, 2026 says the company used $19.8 million in operations in 2025, compared with $16.4 million in 2024. Research and development expense was $4.4 million in 2025, up from $2.6 million in 2024. The annual report says the auditor's report for the year ended December 31, 2023 contained a going concern paragraph about substantial doubt. ## The lead drug and its trial record BeyondSpring describes itself as a clinical stage global biopharmaceutical company. Its lead asset is plinabulin, which the annual report calls a novel brain-penetrant microtubule modulator. The company says plinabulin has been given to over 700 cancer patients with generally good tolerability. The company calls its Phase 3 study in non-small cell lung cancer, DUBLIN-3, successful. That study enrolled 559 patients at 58 clinical sites and compared plinabulin with docetaxel alone for second- and third-line treatment of EGFR wild type disease. The annual report says the combination had a statistically significant overall survival benefit over docetaxel. It also says the benefit was more pronounced in a non-squamous subgroup, with a hazard ratio of 0.72 after additional follow-up and a p-value of 0.0078. The filing presents that as a more pronounced benefit in a subgroup, not as the overall result. Plinabulin is now in a confirmatory global Phase 3 study in the same second- and third-line setting, after progression on prior immune checkpoint inhibitors. The company says it is also developing three small molecule immune agents, which are at the preclinical stage. ## The subsidiary BeyondSpring founded SEED Therapeutics Inc. and continues to hold an equity stake in it. The annual report says SEED uses a targeted protein degradation platform, sometimes called molecular glue technology, and moved its wholly owned lead oncology asset, an RBM39 degrader, into Phase 1 clinical studies in January 2026. SEED is partnering with Eli Lilly and Co. and Eisai Co., Ltd. to discover new chemical entities. ## Who signed Chief Executive Officer Min Qiu signed the 8-K on September 18, 2026. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story BYSI BeyondSpring, Inc. NASDAQ ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/beyondspring-gets-nasdaq-minimum-bid-price-notice-has-until-march-16/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BeyondSpring gets Nasdaq minimum bid price notice", 2026-09-18, https://aibio.space/news/beyondspring-gets-nasdaq-minimum-bid-price-notice-has-until-march-16/